Toll-like receptor 4 (TLR4) pathway adaptor kinases and scaffold proteins

The Toll-like receptor 4 (TLR4) pathway adaptor kinases and scaffold proteins represent a critical intracellular network that translates extracellular pathogen recognition into a robust immune response (Ciesielska et al., 2021, Arch Immunol Ther Exp). Upon activation by ligands such as lipopolysaccharide, TLR4 recruits primary adaptors like MyD88 and TRIF, which then assemble larger signaling complexes including the Myddosome (Kuzmich et al., 2017, Vaccines). These complexes incorporate kinases such as Interleukin-1 receptor-associated kinase 4 (IRAK4) and scaffold proteins like TNF receptor-associated factor 6 (TRAF6) to trigger downstream cascades (Walsh et al., 2015, Nat Rev Immunol). These cascades ultimately activate transcription factors like NF-kappaB and IRFs, leading to the production of pro-inflammatory cytokines and type I interferons (Isler et al., 2020, J Med Chem). Dysregulation of these components is a hallmark of various inflammatory and autoimmune diseases, as well as certain hematologic malignancies like Waldenström macroglobulinemia (Treon et al., 2012, NEJM). Consequently, this pathway is a major focus for drug development, with small-molecule inhibitors of IRAK4 and other downstream nodes currently being evaluated in clinical trials for their ability to modulate aberrant immune signaling (Kuo et al., 2022, Front Immunol).

Other names

TLR4 signaling complexMyddosomeTrifosomeTLR4 downstream signaling molecules

Inhibition of signal transduction downstream of TLR4 by targeting specific kinases (e.g., IRAK4) or disrupting protein-protein interactions between adaptors and scaffolds (Isler et al., 2020, J Med Chem).